Sugi Predict

Sugi Predict / Compounds / SCHEMBL349454

SCHEMBL349454

SCHEMBL349454

COC(=O)C1(c2ccc(Cl)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.55
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ HDAC4 P56524 1/20 0.53
▸ OPRM1 P35372 1/20 0.52
▸ HSD11B1 P28845 6/20 0.51
▸ DRD2 P14416 1/20 0.51
▸ DRD4 P21917 1/20 0.51
▸ DRD3 P35462 1/20 0.51
▸ MAPT P10636 4/20 0.49
▸ LMNA P02545 4/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ THRB P10828 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ HTT P42858 1/20 0.47
▸ CHRM2 P08172 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4939286 0.93 HDAC4 (0.63) ALDH1A1SMN1; SMN2HDAC4OPRM1HSD11B1
SCHEMBL2321833 0.93 HDAC4 (0.58) ALDH1A1SMN1; SMN2HDAC4OPRM1HSD11B1
SCHEMBL5639097 0.91 HDAC4 (0.61) ALDH1A1SMN1; SMN2HDAC4OPRM1HSD11B1
SCHEMBL11629543 0.89 OPRM1 (0.47) ALDH1A1SMN1; SMN2HDAC4OPRM1HSD11B1
SCHEMBL653528 0.89 DRD2 (0.51) ALDH1A1SMN1; SMN2HDAC4OPRM1DRD2
Hydrochloric Acid SCHEMBL4447206 0.87 OPRM1 (0.50) ALDH1A1SMN1; SMN2HDAC4OPRM1DRD2
SCHEMBL20703530 0.86 HDAC4 (0.46) ALDH1A1SMN1; SMN2HDAC4OPRM1HSD11B1
SCHEMBL844453 0.83 OPRM1 (0.53) ALDH1A1SMN1; SMN2OPRM1HSD11B1MAPT
SCHEMBL1464894 0.83 CA12 (0.44) ALDH1A1SMN1; SMN2OPRM1HSD11B1DRD2
SCHEMBL20703420 0.83 HDAC4 (0.44) ALDH1A1SMN1; SMN2HDAC4OPRM1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115572098-B Concrete additive and preparation method thereof 光明铁道控股有限公司 2024-05-28 — — CN claimed
EP-3573972-B1 RORGAMMA MODULATORS AND USES THEREOF GENFIT (FR) 2026-01-14 — — EP disclosed
CN-115572098-B Concrete additive and preparation method thereof 光明铁道控股有限公司 2024-05-28 — — CN disclosed
CN-115572098-A Concrete additive and preparation method thereof 光明铁道控股有限公司 2023-01-06 — — CN disclosed
US-11077115-B2 Rorgamma modulators and uses thereof GENFIT (FR) 2021-08-03 — — US disclosed
US-11077115-B2 Rorgamma modulators and uses thereof GENFIT (FR) 2021-08-03 — — US disclosed
US-20200138030-A1 SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-05-07 — — US disclosed
US-10555526-B2 Substituted oxadiazoles for combating phytopathogenic fungi BASF SE 2020-02-11 — — US disclosed
US-20180317491-A1 SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2018-11-08 — — US disclosed
EP-3370524-A1 SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2018-09-12 — — EP disclosed
US-20080255154-A1 Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes INCYTE CORPORATION (US) 2008-10-16 — — US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 — — EP disclosed
US-7304081-B2 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2007-12-04 — — US disclosed
US-20070179142-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2007-08-02 — — US disclosed
CN-101001842-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2007-07-18 — — CN disclosed
EP-1756063-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-02-28 — — EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 — — WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 — — US disclosed
US-20050282858-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-22 — — US disclosed
WO-2005110992-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2005-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10555526-B2 Substituted oxadiazoles for combating phytopathogenic fungi CYP51A1, OSR1, PAOX ALDH1A1 1187/4885SMN1; SMN2 3029/4885HDAC4 2599/4885
US-20180317491-A1 SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI CYP51A1, OSR1, PAOX ALDH1A1 1187/4885SMN1; SMN2 3029/4885HDAC4 2599/4885
US-20200138030-A1 SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI CYP51A1, OSR1, PAOX ALDH1A1 1187/4885SMN1; SMN2 3029/4885HDAC4 2599/4885
US-20050282858-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 ALDH1A1 311/4885SMN1; SMN2 3627/4885HDAC4 1630/4885
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 ALDH1A1 91/4885SMN1; SMN2 2843/4885HDAC4 414/4885
US-20080255154-A1 Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes HSD11B1, NR3C2, SRD5A1 ALDH1A1 51/4885SMN1; SMN2 4190/4885HDAC4 1374/4885
US-20070179142-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 ALDH1A1 311/4885SMN1; SMN2 3627/4885HDAC4 1630/4885
US-11077115-B2 Rorgamma modulators and uses thereof RORB, RORC, RORA ALDH1A1 761/4885SMN1; SMN2 4792/4885HDAC4 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.